We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
CellProtect Nordic Pharmaceuticals’ (CPNP) therapy candidate CellProtect has received orphan drug designation from the European Commission (EC) to treat multiple myeloma.
Six new medicines, including the first hormone replacement therapy for a thyroid disorder, have been put forward for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use.